HR. 8205
Passed SenateAccelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Updated 2026-10-10
Legislative Impact
Moderate Policy Signal
47
Momentum Score
Low Momentum
35
Reauthorizes through FY2031 and revises federal ALS and rare neurodegenerative disease therapy programs, including research grants, safety reporting, and FDA planning
- Require adverse event reporting
- Direct FDA five year plan
